CDSCO approves AstraZeneca's anti-liver cancer drug combination https://ift.tt/mwRf01X

The primary endpoint was overall survival (OS) for the combination versus sorafenib and secondary endpoints included OS for durvalumab versus sorafenib, objective response rate and progression-free survival (PFS) for the combination and for Durvalumab alone. The trial showed a positive and significant benefit for OS for the combination of Tremelimumab & Durvalumab vs Sorafenib.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/fC2Oilz
Share:

No comments:

Post a Comment

Search This Blog

Powered by Blogger.

Labels

Labels

Blog Archive

Recent Posts

Unordered List

  • Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
  • Aliquam tincidunt mauris eu risus.
  • Vestibulum auctor dapibus neque.

Pages

Theme Support

Need our help to upload or customize this blogger template? Contact me with details about the theme customization you need.